Member Exclusive News

FDA approves first-in-class treatment for rare adrenal tumors

The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.

Go to the profile of Jasmine Harris
Aug 02, 2018

Please sign in or register for FREE

Register to RxNet

RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.